Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of rmhTNF-NC plus cisplatin versus cisplatin intrapleural/intraperitoneal perfusion for malignant pleural or peritoneal effusion
CTR20233523Phase 3Active
- Sponsor
- Shanghai Weike Biopharmaceutical
- Start
- Oct 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rmhTNF-NC in malignant pleural effusion (MPE) and malignant ascites (2 arms), sponsored by Shanghai Weike Biopharmaceutical. Primary endpoint: Puncture-free survival. Started Oct 2024; status: active.
02
Drugs
rmhTNF-NC
03
Conditions
malignant pleural effusion (MPE)malignant ascites
Beyond the preview
Go deeper on CTR20233523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233523.